BIIB Biogen Inc. - Common Stock
关于 Biogen Inc. - Common Stock 公司概况(来自维基百科)
渤健公司 是一所位於美國马萨诸塞州劍橋的生物科技公司,现代生物技术行业最早成立的企业之一,專門從事神經系統疾病、自體免疫性疾病、腫瘤、罕見神經遺傳病藥物的開發。建立於2003年,由渤健與Idec合併而成。
阅读更多
渤健公司(英語:Biogen Inc)是一所位於美國马萨诸塞州劍橋的生物科技公司,现代生物技术行业最早成立的企业之一,專門從事神經系統疾病、自體免疫性疾病、腫瘤、罕見神經遺傳病藥物的開發。建立於2003年,由渤健與Idec合併而成。
## 歷史
1978年,肯尼斯·穆雷、菲利普·夏普、沃特·吉爾伯特與查爾斯·威斯曼(Charles Weissmann)等人在日內瓦成立 Biogen 公司。
1986年,艾弗·羅伊斯頓(Ivor Royston)與霍華德·伯恩多夫(Howard Birndorf),在加州聖地牙哥,成立 IDEC 公司。
2003年,合併 Biogen 與 Idec 兩間公司所組成。
2016年12月20日,Biogen董事會宣布批准Biogen將血友病業務分拆成立獨立上市公司Bioverativ,預計2017年2月1日完成交割。
2018年1月21日賽諾菲(Sanofi)以每股105美元現金,斥資116億美元,收購美國同業Bioverativ。
2019年3月5日,Biogen以每股25.5美元、總值8.77億美元收購英國基因療法公司Nightstar Therapeutics plc ADR(NITE)。
来源:维基百科, CC BY-SA 4.0 · 在维基百科上查看 ↗
BIIB 股票快照 价格、市值、P/E、EPS、ROE、负债/权益、52周范围
BIIB 股价图表 包含技术指标的日 OHLCV — 平移、缩放和自定义您的视图
10年表现 收入、净利润、利润率和每股收益趋势
估值 P/E、P/S、P/B、EV/EBITDA 比率 — 该股票是昂贵还是便宜?
盈利能力 毛利率、营业利润率和净利率;股本回报率 (ROE)、资产回报率 (ROA)、投入资本回报率 (ROIC)
财务健康 债务、流动性、偿付能力 — 资产负债表强度
成长 营收、每股收益 (EPS) 和净利润增长:同比、3年复合年增长率 (CAGR)、5年复合年增长率 (CAGR)
资本效率 资产周转率、库存周转率、应收账款周转率
BIIB 分析师共识 看涨和看跌分析师观点、12个月价格目标、上涨空间
- 强烈买入 9 20.9%
- 买入 20 46.5%
- 持有 13 30.2%
- 卖出 1 2.3%
- 强烈卖出 0 0.0%
12个月价格目标
31 位分析师 · 2026-08-13收益历史 每股收益实际值 vs 预估值,惊喜%,达标率,下次财报日期
| 期间 | EPS Actual | EPS 预期 | 惊喜 |
|---|---|---|---|
| 2026年6月30日 | $3.60 | $3.01 | 0.59% |
| 2026年3月31日 | $3.57 | $2.83 | 0.74% |
| 2025年12月31日 | $1.99 | $1.65 | 0.34% |
| 2025年9月30日 | $4.81 | $3.96 | 0.85% |
| 2025年6月30日 | $5.47 | $3.94 | 1.5% |
| 2025年3月31日 | $3.02 | $2.58 | 0.44% |
同行比较(GICS 子行业) 关键指标与行业同行对比
| 股票代码 | 市值 | P/E | 营收同比增长 | 净利润率 | ROE | 毛利率 |
|---|---|---|---|---|---|---|
| BIIB | $25.84B | 20.0 | 2.2% | 13.1% | 7.2% | — |
| VRTX | $115.15B | 29.6 | 8.9% | 32.9% | 22.1% | — |
| REGN | $106.21B | 18.6 | 0.99% | 31.4% | 14.7% | — |
| RVMD | — | — | — | — | — | — |
| NTRA | $32.00B | -150.7 | 35.9% | -9.0% | -14.1% | — |
| ALNY | $52.64B | 170.7 | 65.2% | 8.5% | 60.4% | — |
| INSM | $37.29B | -27.1 | 66.7% | -210.5% | -128.4% | — |
| INCY | $19.60B | 15.4 | 21.2% | 25.0% | 27.6% | — |
| MRNA | $11.62B | -4.1 | -39.9% | -145.2% | -31.3% | — |
| UTHR | $21.27B | 17.5 | 10.6% | 41.9% | 18.7% | 87.9% |
完整基本面 所有年度指标 — 损益表、资产负债表、现金流量表
损益表 17
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $9.89B | $9.68B | $9.84B | $10.17B | $10.98B | $13.44B | $14.38B | $13.45B | $12.27B | $11.45B | $10.76B | $9.70B | |
| Cost of Revenue | $2.40B | $2.31B | $2.53B | $2.28B | $2.11B | $1.81B | $1.96B | $1.82B | $1.63B | $1.48B | $1.24B | $1.17B | |
| Gross Profit | · | · | · | · | · | $11.64B | $12.42B | $11.64B | $10.64B | $9.97B | $9.52B | $8.53B | |
| SG&A Expense | $2.43B | $2.40B | $2.55B | $2.40B | $2.67B | $2.50B | $2.37B | $2.11B | $1.93B | $1.95B | $2.11B | $2.23B | |
| Operating Expenses | $8.33B | $7.77B | $8.54B | $6.58B | $9.24B | $8.40B | $7.34B | $7.56B | $6.93B | $6.30B | $5.87B | $5.75B | |
| Operating Income | · | · | · | · | $2.84B | $4.55B | $7.04B | $5.89B | $5.35B | $5.15B | $4.89B | $3.97B | |
| Interest Expense | $268M | $250M | $247M | $247M | $254M | $222M | $187M | $201M | $251M | $260M | $96M | $30M | |
| Interest Income | $125M | $68M | $276M | $89M | $11M | $42M | $120M | $112M | $78M | $63M | $22M | $12M | |
| Other Non-op | $-25M | $3M | $-400.0K | $10M | $6M | $-3M | $-47M | $-10M | $-15M | $-18M | $-14M | $-26M | |
| Pretax Income | $1.56B | $1.91B | $1.30B | $3.59B | $1.75B | $5.05B | $7.13B | $5.90B | $5.13B | $4.93B | $4.77B | $3.95B | |
| Income Tax | $264M | $274M | $135M | $633M | $52M | $992M | $1.16B | $1.43B | $2.46B | $1.24B | $1.16B | $990M | |
| Net Income | $1.29B | $1.63B | $1.16B | $3.05B | $1.56B | $4.00B | $5.89B | $4.43B | $2.54B | $3.70B | $3.55B | $2.93B | |
| EPS (Basic) | $8.83 | $11.21 | $8.02 | $20.96 | $10.44 | $24.86 | $31.47 | $21.63 | $11.94 | $16.96 | $15.38 | $12.42 | |
| EPS (Diluted) | $8.79 | $11.18 | $7.97 | $20.87 | $10.40 | $24.80 | $31.42 | $21.58 | $11.92 | $16.93 | $15.34 | $12.37 | |
| Shares (Basic) | 146,500,000 | 145,600,000 | 144,700,000 | 145,300,000 | 149,100,000 | 160,900,000 | 187,100,000 | 204,900,000 | 212,600,000 | 218,400,000 | 230,700,000 | 236,400,000 | |
| Shares (Diluted) | 147,100,000 | 145,900,000 | 145,600,000 | 146,000,000 | 149,600,000 | 161,300,000 | 187,400,000 | 205,300,000 | 213,000,000 | 218,800,000 | 231,200,000 | 237,200,000 | |
| EBITDA | $780M | $673M | $495M | $518M | $3.33B | $5.01B | $7.72B | $6.91B | $6.43B | $5.83B | $5.49B | $4.66B |
资产负债表 29
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Cash & Equivalents | · | · | · | · | · | · | $2.91B | $1.22B | $1.57B | $2.33B | $1.31B | $1.20B | |
| Short-term Investments | · | · | · | · | · | · | $1.56B | $2.31B | $2.12B | $2.57B | $2.12B | $640M | |
| Receivables | $1.34B | $1.40B | $1.66B | $1.71B | $1.55B | $1.91B | $1.88B | $1.96B | $1.79B | $1.44B | $1.23B | $1.29B | |
| Inventory | $2.17B | $2.46B | $2.53B | $1.34B | $1.35B | $1.07B | $804M | $930M | $903M | $1.00B | $893M | $804M | |
| Other Current Assets | $1.12B | $752M | $1.18B | $1.42B | $741M | $881M | $631M | $688M | $962M | $1.09B | $837M | $310M | |
| Current Assets | $8.97B | $7.46B | $6.86B | $9.79B | $7.86B | $6.89B | $8.38B | $7.64B | $7.87B | $8.73B | $6.70B | $4.54B | |
| PP&E (Net) | $3.06B | $3.18B | $3.31B | $3.30B | $3.42B | $3.41B | $3.25B | $3.60B | $3.18B | $2.50B | $2.19B | $1.77B | |
| PP&E (Gross) | $5.99B | $5.85B | $5.71B | $5.46B | $5.42B | $5.19B | $4.84B | $5.40B | $4.74B | $3.94B | $3.52B | $2.95B | |
| Accum. Depreciation | $2.90B | $2.67B | $2.40B | $2.17B | $2.01B | $1.78B | $1.59B | $1.80B | $1.56B | $1.44B | $1.33B | $1.19B | |
| Goodwill | $6.49B | $6.48B | $6.22B | $5.75B | $5.76B | $5.76B | $5.76B | $5.71B | $4.63B | $3.67B | $2.66B | $1.76B | |
| Intangibles | $9.18B | $9.69B | $8.36B | $1.85B | $2.22B | $3.08B | $3.53B | $3.12B | $3.88B | $3.81B | $4.09B | $4.03B | |
| Other Non-current Assets | $751M | $560M | $745M | $1.53B | $1.94B | $2.90B | $1.25B | $1.69B | $432M | $1.34B | $1.11B | $755M | |
| Total Assets | $29.44B | $28.05B | $26.84B | $24.55B | $23.88B | $24.62B | $27.23B | $25.29B | $23.65B | $22.88B | $19.50B | $14.31B | |
| Accounts Payable | $432M | $424M | $403M | $492M | $589M | $455M | $531M | $370M | $396M | $280M | $267M | $229M | |
| Short-term Debt | · | $1.75B | $150M | $0 | $999M | $0 | $1.50B | $0 | · | · | · | · | |
| Current Liabilities | $3.35B | $5.53B | $3.43B | $3.27B | $4.30B | $3.74B | $4.86B | $3.30B | $3.37B | $3.42B | $2.58B | $2.22B | |
| Capital Leases | $290M | $334M | $400M | $333M | $330M | $402M | $413M | $0 | · | · | · | · | |
| Deferred Tax | $508M | $190M | $642M | $335M | $694M | $1.03B | $2.81B | $1.64B | $123M | $93M | $125M | $52M | |
| Other Non-current Liabilities | $748M | $732M | $781M | $944M | $1.32B | $1.33B | $1.35B | $1.39B | $1.63B | $722M | $906M | $650M | |
| Total Liabilities | $11.18B | $11.33B | $12.05B | $11.17B | $12.92B | $13.93B | $13.90B | $12.26B | $11.05B | $10.75B | $10.13B | $3.50B | |
| Long-term Debt | $6.29B | $4.55B | $6.79B | $6.28B | $6.27B | $7.43B | $4.46B | $5.94B | $5.93B | $6.51B | $6.52B | $580M | |
| Common Stock | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | $100.0K | |
| Paid-in Capital | $863M | $569M | $302M | $73M | $68M | $0 | $0 | $0 | $98M | $0 | $0 | $4.20B | |
| Retained Earnings | $20.55B | $19.26B | $17.63B | $16.47B | $13.91B | $13.98B | $16.46B | $16.26B | $15.81B | $15.07B | $12.21B | $9.28B | |
| Treasury Stock | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.61B | $2.61B | $2.61B | |
| AOCI | $-182M | $-136M | $-154M | $-165M | $-107M | $-299M | $-135M | $-240M | $-318M | $-320M | $-224M | $-60M | |
| Stockholders' Equity | $18.26B | $16.72B | $14.80B | $13.39B | $10.96B | $10.70B | $13.34B | $13.04B | $12.61B | $12.14B | $9.37B | $10.81B | |
| Liabilities + Equity | $29.44B | $28.05B | $26.84B | $24.55B | $23.88B | $24.62B | $27.23B | $25.29B | $23.65B | $22.88B | $19.50B | $14.31B | |
| Shares Outstanding | 170,500,000 | 169,500,000 | 144,900,000 | 167,900,000 | 170,800,000 | 176,200,000 | 174,200,000 | 197,200,000 | 211,500,000 | 215,900,000 | 218,600,000 | 234,600,000 |
现金流 18
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $780M | $673M | $495M | $518M | $488M | $457M | $465M | $650M | $1.08B | $683M | $600M | $688M | |
| Stock-based Comp | $291M | $291M | $264M | $254M | $239M | $198M | $182M | $158M | $128M | $155M | $161M | $155M | |
| Deferred Tax | $362M | $-158M | $-306M | $-169M | $-427M | $149M | $67M | $108M | $92M | $-175M | $-146M | $-308M | |
| Amort. of Intangibles | $507M | $386M | $241M | $246M | $252M | $255M | $274M | $381M | $455M | $373M | $383M | $490M | |
| Restructuring | $49M | $30M | $219M | $131M | $0 | $0 | $2M | $12M | $900.0K | $33M | $93M | $0 | |
| Other Non-cash | $-521M | $437M | $-67M | $-2.27B | $1.78B | $-575M | $260M | $475M | $711M | $157M | $-447M | $-528M | |
| Operating Cash Flow | $2.20B | $2.88B | $1.55B | $1.38B | $3.64B | $4.23B | $7.08B | $6.19B | $4.55B | $4.59B | $3.92B | $2.94B | |
| CapEx | $154M | $154M | $277M | $240M | $258M | $425M | $514M | $771M | $867M | $616M | $643M | $288M | |
| Investing Cash Flow | $-1.37B | $-799M | $-4.10B | $1.58B | $-564M | $-609M | $470M | $-2.05B | $-2.96B | $-2.48B | $-4.55B | $-1.54B | |
| Debt Issued | $1.73B | $0 | $997M | $0 | $0 | $2.97B | $0 | $0 | · | · | · | · | |
| Net Debt Issued | $-17M | $0 | $997M | $0 | $0 | $2.97B | · | · | · | · | · | · | |
| Stock Repurchased | · | $0 | $0 | $750M | $1.80B | $6.68B | $5.87B | $4.35B | $1.37B | $1.00B | $5.00B | $887M | |
| Net Stock Activity | · | $0 | $0 | $-750M | $-1.80B | $-6.68B | $-5.87B | $-4.35B | $-1.37B | $-1.00B | $-5.00B | $-887M | |
| Financing Cash Flow | $-302M | $-684M | $149M | $-1.75B | $-2.09B | $-5.27B | $-5.86B | $-4.47B | $-2.38B | $-1.05B | $783M | $-756M | |
| Net Change in Cash | · | · | · | · | · | · | · | · | $-792M | $1.05B | $149M | $643M | |
| Taxes Paid | $864M | $355M | $741M | $933M | $248M | $907M | $1.06B | $1.01B | $1.07B | $1.64B | $1.67B | $1.16B | |
| Free Cash Flow | $2.05B | $2.72B | $1.27B | $1.14B | $3.38B | $3.81B | $6.56B | $5.42B | $3.68B | $3.91B | $3.07B | $2.65B | |
| Levered FCF | $1.83B | $2.51B | $1.05B | $941M | $3.14B | $3.63B | $6.41B | $5.26B | $3.55B | $3.71B | $3.00B | $2.63B |
盈利能力 8
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Gross Margin | · | · | · | · | · | 86.6% | 86.4% | 86.5% | 86.7% | 87.1% | 88.5% | 87.9% | |
| Operating Margin | · | · | · | · | 25.9% | 33.8% | 49.0% | 43.8% | 43.5% | 45.0% | 45.4% | 40.9% | |
| Net Margin | 13.1% | 16.9% | 11.8% | 29.9% | 14.2% | 29.8% | 41.0% | 32.9% | 20.7% | 32.3% | 33.0% | 30.2% | |
| Pretax Margin | 15.7% | 19.7% | 13.2% | 35.3% | 15.9% | 37.5% | 49.6% | 43.9% | 41.8% | 43.1% | 44.3% | 40.7% | |
| EBITDA Margin | 7.9% | 7.0% | 5.0% | 5.1% | 30.3% | 37.2% | 53.7% | 51.3% | 52.3% | 50.9% | 51.0% | 48.0% | |
| ROA | 4.5% | 5.9% | 4.5% | 12.6% | 6.4% | 15.4% | 22.4% | 18.1% | 10.9% | 17.5% | 21.0% | 22.4% | |
| ROE | 7.2% | 9.9% | 7.9% | 25.0% | 14.4% | 33.3% | 44.8% | 33.1% | 20.5% | 34.4% | 35.1% | 30.2% | |
| ROIC | · | · | · | · | 25.3% | 34.2% | 44.2% | 34.2% | 22.1% | 31.8% | 39.5% | 27.5% |
流动性与偿付能力 3
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 2.7 | 1.3 | 2.0 | 3.0 | 1.8 | 1.8 | 1.7 | 2.3 | 2.3 | 2.6 | 2.6 | 2.1 | |
| Quick Ratio | 0.4 | 0.3 | 0.5 | 0.5 | 0.4 | 0.5 | 1.3 | 1.7 | 1.6 | 1.9 | 1.8 | 1.4 | |
| Interest Coverage | · | · | · | · | 11.2 | 20.4 | 37.6 | 29.4 | 21.3 | 19.8 | 51.2 | 134.7 |
效率 3
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.3 | 0.4 | 0.4 | 0.4 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.5 | 0.6 | 0.7 | |
| Inventory Turnover | 1.0 | 0.9 | 1.3 | 1.7 | 1.7 | 1.9 | 2.3 | 2.0 | 1.7 | 1.6 | 1.5 | 1.6 | |
| Receivables Turnover | 7.2 | 6.3 | 5.8 | 6.3 | 6.3 | 7.1 | 7.5 | 7.2 | 7.6 | 8.6 | 8.5 | 9.2 |
增长率 9
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue YoY | 2.2% | -1.6% | -3.3% | -7.4% | -18.3% | · | · | · | · | · | · | · | |
| Revenue CAGR 3Y | -0.94% | -4.1% | -9.9% | · | · | · | · | · | · | · | · | · | |
| Revenue CAGR 5Y | -6.0% | · | · | · | · | · | · | · | · | · | · | · | |
| EPS YoY | -21.4% | 40.3% | -61.8% | 100.7% | -58.1% | · | · | · | · | · | · | · | |
| EPS CAGR 3Y | -25.0% | 2.4% | -31.5% | · | · | · | · | · | · | · | · | · | |
| EPS CAGR 5Y | -18.7% | · | · | · | · | · | · | · | · | · | · | · | |
| Net Income YoY | -20.8% | 40.6% | -61.9% | 95.8% | -61.1% | · | · | · | · | · | · | · | |
| Net Income CAGR 3Y | -24.9% | 1.6% | -33.8% | · | · | · | · | · | · | · | · | · | |
| Net Income CAGR 5Y | -20.2% | · | · | · | · | · | · | · | · | · | · | · |
估值 (TTM) 10
| 指标 | 趋势 | 2025 | 2024 | 2023 | 2022 | 2021 | 2020 | 2019 | 2018 | 2017 | 2016 | 2015 | 2014 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $9.89B | $9.68B | $9.84B | $10.17B | $10.98B | $13.44B | $14.38B | $13.45B | $12.27B | $11.45B | $10.76B | $9.70B | |
| Net Income TTM | $1.29B | $1.63B | $1.16B | $3.05B | $1.56B | $4.00B | $5.89B | $4.43B | $2.54B | $3.70B | $3.55B | $2.93B | |
| Market Cap | $25.84B | $22.30B | $37.50B | $39.88B | $35.27B | $37.32B | $51.69B | $59.34B | $67.38B | $61.22B | $66.97B | $79.62B | |
| P/E | 20.0 | 13.7 | 32.5 | 13.3 | 23.1 | 9.9 | 9.4 | 13.9 | 26.7 | 16.8 | 20.0 | 27.4 | |
| P/S | 2.6 | 2.3 | 3.8 | 3.9 | 3.2 | 2.8 | 3.6 | 4.4 | 5.5 | 5.3 | 6.2 | 8.2 | |
| P/B | 1.4 | 1.3 | 2.5 | 3.0 | 3.2 | 3.5 | 3.9 | 4.6 | 5.3 | 5.0 | 7.1 | 7.4 | |
| P / Tangible Book | 10.0 | 40.8 | 172.6 | 6.9 | 11.8 | 20.1 | · | · | · | · | · | · | |
| P / Cash Flow | 11.7 | 7.8 | 24.2 | 28.8 | 9.7 | 8.8 | 7.3 | 9.6 | 14.8 | 13.5 | 18.0 | 27.1 | |
| P / FCF | 12.6 | 8.2 | 29.5 | 34.9 | 10.4 | 9.8 | 7.9 | 11.0 | 18.3 | 15.7 | 21.8 | 30.0 | |
| Earnings Yield | 5.0% | 7.3% | 3.1% | 7.5% | 4.3% | 10.1% | 10.6% | 7.2% | 3.7% | 6.0% | 5.0% | 3.6% |
损益表 15
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | $2.74B | $2.48B | $2.28B | $2.53B | $2.65B | $2.43B | $2.45B | $2.47B | $2.46B | $2.29B | $2.39B | $2.53B | $2.46B | $2.46B | $2.54B | $2.51B | |
| Cost of Revenue | $777M | $661M | $496M | $674M | $605M | $629M | $584M | $639M | $546M | $542M | $618M | $660M | $593M | $663M | $571M | $470M | |
| SG&A Expense | $710M | $607M | $682M | $595M | $584M | $572M | $680M | $588M | $554M | $582M | $608M | $788M | $548M | $605M | $633M | $563M | |
| Operating Expenses | $2.60B | $2.10B | $2.34B | $1.98B | $1.90B | $2.12B | $2.16B | $2.01B | $1.77B | $1.83B | $2.09B | $2.67B | $1.75B | $2.02B | $1.94B | $1.14B | |
| Interest Expense | $82M | $68M | $68M | $67M | $73M | $60M | $60M | $60M | $61M | $69M | $72M | $64M | $49M | $62M | $55M | $60M | |
| Interest Income | $25M | $38M | $37M | $32M | $32M | $24M | $18M | $12M | $20M | $17M | $24M | $96M | $76M | $81M | $50M | $24M | |
| Other Non-op | $3M | $-1M | $-37M | $16M | $2M | $2M | $8M | $-800.0K | $-2M | $-2M | $5M | $-3M | $-2M | $600.0K | $35M | $2M | |
| Pretax Income | $132M | $378M | $-56M | $557M | $744M | $311M | $292M | $451M | $699M | $465M | $292M | $-141M | $708M | $438M | $604M | $1.37B | |
| Income Tax | $35M | $58M | $-7M | $91M | $109M | $71M | $25M | $62M | $115M | $71M | $43M | $-73M | $115M | $51M | $54M | $236M | |
| Net Income | $98M | $320M | $-49M | $466M | $635M | $240M | $267M | $388M | $584M | $393M | $250M | $-68M | $592M | $388M | $550M | $1.13B | |
| EPS (Basic) | $0.66 | $2.17 | $-0.33 | $3.18 | $4.33 | $1.65 | $1.82 | $2.67 | $4.01 | $2.71 | $1.71 | $-0.47 | $4.09 | $2.69 | $3.79 | $7.86 | |
| EPS (Diluted) | $0.66 | $2.15 | $-0.35 | $3.17 | $4.33 | $1.64 | $1.82 | $2.66 | $4.00 | $2.70 | $1.70 | $-0.47 | $4.07 | $2.67 | $3.73 | $7.84 | |
| Shares (Basic) | 147,700,000 | 147,200,000 | -292,700,000 | 146,600,000 | 146,500,000 | 146,100,000 | -290,900,000 | 145,700,000 | 145,600,000 | 145,200,000 | -289,200,000 | 144,800,000 | 144,700,000 | 144,400,000 | -292,100,000 | 144,400,000 | |
| Shares (Diluted) | 148,700,000 | 148,400,000 | -293,300,000 | 147,100,000 | 146,700,000 | 146,600,000 | -292,000,000 | 146,100,000 | 145,900,000 | 145,900,000 | -289,900,000 | 144,800,000 | 145,500,000 | 145,200,000 | -292,600,000 | 144,800,000 | |
| EBITDA | · | $204M | · | · | · | $183M | · | · | · | $148M | · | · | · | $112M | · | · |
资产负债表 28
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Receivables | · | · | $1.34B | · | · | · | $1.40B | · | · | · | · | · | · | $1.63B | · | $1.57B | |
| Inventory | $2.38B | $1.95B | $2.17B | $2.21B | $2.27B | $2.27B | $2.46B | $2.47B | $2.51B | $2.52B | · | $2.98B | $1.33B | $1.28B | · | $1.38B | |
| Other Current Assets | $1.24B | $1.17B | $1.12B | $917M | $851M | $757M | $752M | $674M | $615M | $1.17B | · | $974M | $896M | $1.41B | · | $1.50B | |
| Current Assets | $7.31B | $9.19B | $8.97B | $8.94B | $7.97B | $7.63B | $7.46B | $6.83B | $7.11B | $6.76B | · | $8.45B | $10.43B | $9.76B | · | $9.77B | |
| PP&E (Net) | $2.99B | $3.02B | $3.06B | $3.08B | $3.10B | $3.13B | $3.18B | $3.21B | $3.25B | $3.28B | · | $3.30B | $3.31B | $3.30B | · | $3.27B | |
| PP&E (Gross) | · | · | $5.99B | · | · | · | $5.85B | · | · | · | · | · | · | · | · | · | |
| Accum. Depreciation | $3.10B | $3.00B | $2.93B | $2.87B | $2.81B | $2.74B | $2.67B | $2.60B | $2.54B | $2.47B | · | $2.34B | $2.28B | $2.22B | · | $2.10B | |
| Goodwill | $6.99B | $6.49B | $6.49B | $6.49B | $6.49B | $6.48B | $6.48B | $6.49B | $6.23B | $6.23B | $6.22B | $6.81B | $5.75B | $5.75B | $5.75B | $5.74B | |
| Intangibles | $13.52B | $9.05B | $9.18B | $9.33B | $9.47B | $9.58B | $9.69B | $9.81B | $8.23B | $8.28B | · | $7.34B | $1.78B | $1.81B | · | $2.01B | |
| Other Non-current Assets | $832M | $778M | $751M | $730M | $638M | $559M | $560M | $631M | $682M | $698M | · | $755M | $1.10B | $1.38B | · | $1.61B | |
| Total Assets | $32.09B | $29.48B | $29.44B | $29.21B | $28.33B | $28.03B | $28.05B | $28.31B | $26.80B | $26.57B | · | $28.19B | $25.16B | $24.60B | · | $24.85B | |
| Accounts Payable | $404M | $358M | $432M | $413M | $408M | $392M | $424M | $423M | $354M | $387M | · | $440M | $445M | $491M | · | $383M | |
| Short-term Debt | · | · | · | $0 | $0 | $1.75B | · | $1.75B | $0 | $250M | · | $500M | · | · | · | $0 | |
| Current Liabilities | $3.92B | $3.00B | $3.35B | $3.29B | $3.18B | $5.30B | $5.53B | $5.42B | $3.11B | $3.22B | · | $5.02B | $3.19B | $3.01B | · | $3.93B | |
| Capital Leases | $265M | $273M | $290M | $305M | $311M | $323M | $334M | $357M | $368M | $406M | · | $429M | $304M | $327M | · | $355M | |
| Deferred Tax | $946M | $484M | $508M | $358M | $118M | $133M | $190M | $882M | $591M | $658M | · | $728M | $144M | $251M | · | $329M | |
| Other Non-current Liabilities | $821M | $787M | $748M | $762M | $800M | $752M | $732M | $744M | $557M | $777M | · | $748M | $777M | $936M | · | $1.20B | |
| Total Liabilities | $13.24B | $10.83B | $11.18B | $11.00B | $10.70B | $11.05B | $11.33B | $11.95B | $10.91B | $11.35B | · | $13.71B | $10.70B | $10.81B | · | $12.09B | |
| Long-term Debt | $7.29B | $6.29B | $6.29B | $6.29B | $6.28B | $4.55B | · | $4.55B | $6.29B | $6.29B | · | $6.79B | $6.28B | $6.28B | · | $6.28B | |
| Total Debt | · | · | · | $0 | $0 | $1.75B | · | $1.75B | $0 | $250M | · | $500M | · | · | · | $0 | |
| Common Stock | $100.0K | $100.0K | · | $100.0K | $100.0K | $100.0K | · | $100.0K | $100.0K | $100.0K | · | $100.0K | $100.0K | $100.0K | · | $100.0K | |
| Paid-in Capital | $983M | $897M | $863M | $798M | $714M | $630M | $569M | $488M | $408M | $330M | · | $242M | $171M | $91M | · | $0 | |
| Retained Earnings | $20.97B | $20.87B | $20.55B | $20.60B | $20.14B | $19.50B | $19.26B | $18.99B | $18.60B | $18.02B | · | $17.38B | $17.45B | $16.85B | · | $15.92B | |
| Treasury Stock | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | $2.98B | · | $2.98B | $2.98B | $2.98B | · | $2.98B | |
| AOCI | $-128M | $-140M | $-182M | $-215M | $-238M | $-174M | $-136M | $-146M | $-146M | $-160M | · | $-159M | $-173M | $-172M | · | $-164M | |
| Stockholders' Equity | $18.85B | $18.65B | $18.26B | $18.21B | $17.63B | $16.98B | $16.72B | $16.36B | $15.89B | $15.21B | $14.80B | $14.48B | $14.47B | $13.80B | $13.39B | $12.78B | |
| Liabilities + Equity | $32.09B | $29.48B | $29.44B | $29.21B | $28.33B | $28.03B | $28.05B | $28.31B | $26.80B | $26.57B | · | $28.19B | $25.16B | $24.60B | · | $24.85B | |
| Shares Outstanding | 171,500,000 | 171,400,000 | 146,800,000 | 170,500,000 | 170,400,000 | 170,300,000 | 145,800,000 | 169,500,000 | 169,500,000 | 169,400,000 | 144,900,000 | 168,700,000 | 168,600,000 | 168,600,000 | 144,000,000 | 167,800,000 |
现金流 15
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| D&A | $236M | $204M | $200M | $202M | $194M | $183M | $184M | $183M | $159M | $148M | $140M | $125M | $117M | $112M | $120M | $121M | |
| Stock-based Comp | $77M | $84M | $60M | $75M | $75M | $81M | $75M | $73M | $71M | $73M | $55M | $62M | $72M | $76M | $67M | $64M | |
| Deferred Tax | $-28M | $24M | $167M | $254M | $-31M | $-28M | $-58M | $-53M | $-87M | $40M | $72M | $-207M | $-106M | $-64M | $-29M | $-92M | |
| Amort. of Intangibles | $168M | · | $132M | $136M | $127M | · | $111M | $110M | $87M | · | · | · | · | · | · | · | |
| Restructuring | $165M | $8M | $7M | $7M | $-700.0K | $35M | $5M | $7M | $7M | $12M | $99M | $76M | $34M | $10M | $7M | $15M | |
| Other Non-cash | · | $14M | · | · | · | $-218M | · | · | · | $-100M | · | · | · | $-56M | · | · | |
| Operating Cash Flow | $449M | $646M | $512M | $1.27B | $161M | $259M | $761M | $936M | $626M | $553M | $12M | $592M | $487M | $455M | $-175M | $661M | |
| CapEx | $41M | $51M | $44M | $46M | $27M | $37M | $39M | $35M | $34M | $46M | $65M | $74M | $71M | $67M | $86M | $59M | |
| Investing Cash Flow | $-3.84B | $-210M | $-1.23B | $-35M | $-57M | $-47M | $-19M | $-1.18B | $466M | $-66M | $-652M | $-1.74B | $-754M | $-953M | $-141M | $1.67B | |
| Debt Issued | · | · | $0 | $-300.0K | · | · | $0 | $0 | · | · | $0 | · | · | · | $0 | · | |
| Net Debt Issued | · | · | · | · | · | $0 | · | · | · | $-400M | · | · | · | · | · | · | |
| Stock Repurchased | · | · | · | · | · | · | · | · | · | · | · | $0 | · | · | $0 | $250M | |
| Financing Cash Flow | $1.30B | $-44M | $-137M | $-130M | $-12M | $-23M | $8M | $-7M | $-245M | $-440M | $-646M | $849M | $-10M | $-43M | $-7M | $-1.25B | |
| Free Cash Flow | · | $594M | · | · | · | $222M | · | · | · | $507M | · | · | · | $389M | · | · | |
| Levered FCF | · | $537M | · | · | · | $176M | · | · | · | $449M | · | · | · | $333M | · | · |
盈利能力 5
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Net Margin | 3.6% | 12.9% | · | 18.4% | 24.0% | 9.9% | · | 15.8% | 23.7% | 17.2% | · | -2.7% | 24.1% | 15.8% | · | 45.2% | |
| Pretax Margin | 4.8% | 15.2% | · | 22.0% | 28.1% | 12.8% | · | 18.3% | 28.3% | 20.3% | · | -5.6% | 28.8% | 17.8% | · | 54.7% | |
| EBITDA Margin | · | 8.2% | · | · | · | 7.5% | · | · | · | 6.4% | · | · | · | 4.6% | · | · | |
| ROA | 0.32% | 1.1% | · | 1.6% | 2.3% | 0.88% | · | 1.4% | 2.2% | 1.5% | · | -0.26% | 2.4% | 1.6% | · | 4.7% | |
| ROE | 0.53% | 1.8% | · | 2.7% | 3.8% | 1.5% | · | 2.5% | 3.9% | 2.7% | · | -0.50% | 4.7% | 3.0% | · | 9.8% |
流动性与偿付能力 3
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Current Ratio | 1.9 | 3.1 | · | 2.7 | 2.5 | 1.4 | · | 1.3 | 2.3 | 2.1 | · | 1.7 | 3.3 | 3.2 | · | 2.5 | |
| Quick Ratio | · | · | · | · | · | · | · | · | · | · | · | · | · | 0.5 | · | 0.4 | |
| Debt / Equity | · | · | · | 0.0 | 0.0 | 0.1 | · | 0.1 | 0.0 | 0.0 | · | 0.0 | · | · | · | 0.0 |
效率 3
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Asset Turnover | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | 0.1 | 0.1 | · | 0.1 | |
| Inventory Turnover | 0.3 | 0.3 | · | 0.3 | 0.3 | 0.3 | · | 0.2 | 0.3 | 0.3 | · | 0.3 | 0.5 | 0.5 | · | 0.3 | |
| Receivables Turnover | · | · | · | · | · | · | · | · | · | · | · | · | · | 1.5 | · | 1.5 |
估值 (TTM) 10
| 指标 | 趋势 | Q2 2026 | Q1 2026 | Q4 2025 | Q3 2025 | Q2 2025 | Q1 2025 | Q4 2024 | Q3 2024 | Q2 2024 | Q1 2024 | Q4 2023 | Q3 2023 | Q2 2023 | Q1 2023 | Q4 2022 | Q3 2022 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue TTM | $10.39B | $10.09B | · | $10.08B | $10.01B | $9.65B | · | $9.75B | $9.74B | $9.74B | · | $9.96B | $10.02B | $10.09B | · | $10.41B | |
| Net Income TTM | $1.52B | $1.66B | · | $1.73B | $1.85B | $1.61B | · | $1.30B | $1.50B | $1.30B | · | $2.05B | $3.17B | $2.88B | · | $2.83B | |
| Market Cap | $37.05B | $31.42B | · | $23.88B | $21.40B | $23.30B | · | $32.86B | $39.29B | $36.53B | · | $43.36B | $48.03B | $46.88B | · | $44.80B | |
| P/E | 21.0 | 16.2 | · | 11.9 | 9.9 | 12.4 | · | 21.8 | 22.5 | 24.0 | · | 18.2 | 13.1 | 14.0 | · | 13.8 | |
| P/S | 3.6 | 3.1 | · | 2.4 | 2.1 | 2.4 | · | 3.4 | 4.0 | 3.8 | · | 4.4 | 4.8 | 4.6 | · | 4.3 | |
| P/B | 2.0 | 1.7 | · | 1.3 | 1.2 | 1.4 | · | 2.0 | 2.5 | 2.4 | · | 3.0 | 3.3 | 3.4 | · | 3.5 | |
| P / Tangible Book | · | 10.1 | · | 10.0 | 12.8 | 25.4 | · | 486.0 | 27.5 | 52.1 | · | 130.7 | 6.9 | 7.5 | · | 8.9 | |
| P / Cash Flow | · | 48.7 | · | · | · | 89.9 | · | · | · | 66.0 | · | · | · | 103.0 | · | · | |
| P / FCF | · | 52.9 | · | · | · | 104.9 | · | · | · | 72.0 | · | · | · | 120.6 | · | · | |
| Earnings Yield | 4.8% | 6.2% | · | 8.4% | 10.1% | 8.0% | · | 4.6% | 4.4% | 4.2% | · | 5.5% | 7.7% | 7.1% | · | 7.2% |
财务报表 损益表、资产负债表、现金流量表 — 年度,近5年
损益表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 收入 | $9.89B | $9.68B | $9.84B | $10.17B | $10.98B |
| 营业利润率 % | — | — | — | — | 25.9% |
| 净收入 | $1.29B | $1.63B | $1.16B | $3.05B | $1.56B |
| 稀释后每股收益 (EPS) | $8.79 | $11.18 | $7.97 | $20.87 | $10.40 |
资产负债表
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 流动比率 | 2.7 | 1.3 | 2.0 | 3.0 | 1.8 |
| 速动比率 | 0.4 | 0.3 | 0.5 | 0.5 | 0.4 |
现金流
| 2025-12-31 | 2024-12-31 | 2023-12-31 | 2022-12-31 | 2021-12-31 | |
|---|---|---|---|---|---|
| 自由现金流 | $2.05B | $2.72B | $1.27B | $1.14B | $3.38B |
最新新闻 提及该公司的近期头条新闻
- What Makes Denali Therapeutics (DNLI) One of the Best AI Driven Biotech Names
- Biogen 将阿尔茨海默病药物推进至后期试验,尽管数据显示令人失望
- 为什么周三生物科技公司百杰康股票表现出色
- 以下是周二的华尔街顶级分析师研究报告:百健、勃肯斯托克、Fastly、福特、Lennox International、Netskope、SanDisk、特斯拉等
- 为什么比奥根股票在周一被重创
- Apellis Pharma 股价飙升,因百健达成交易。现在追逐 APLS 股票是否太晚了?
- Biogen将以56亿美元收购Apellis Pharmaceuticals,将其C3疗法纳入投资组合
交易信号 近期买入/卖出信号,包含入场价和风险/回报比
我的指标 您的个人关注列表 — 来自完整基本面的选定行
选择对您重要的指标 — 点击上方完整基本面中任意行的 ➕。
您的选择已保存,并会跟随您浏览所有股票。
机构持有人 (13F) 1148 家申报者 · $23.5B 总计 · 截至 2026年6月30日
在其季度SEC表格13F中报告持有此股票的机构。仅限多头头寸;单个申报人可能因单独的期权腿而出现两次。 大的抵消性看跌/看涨腿通常反映做市或对冲库存,而非方向性判断。
| 新仓位 | 已退出持仓 | 增加 | 减少 | 净股数变动 |
|---|---|---|---|---|
| 134 (-32 与上一季度对比) | 77 (-22 与上一季度对比) | 409 (+25 与上一季度对比) | 295 (-3 与上一季度对比) | +6.6M |
与Q1 2026对比。 SEC 13F表格的提交截止日期是季度末后45天,外加少量延迟提交的缓冲期——在此窗口期内的季度将被跳过,优先显示最近一个已完整报告的季度对。
| 机构 | 价值 | 股份 | % 已追踪的13F | 类型 |
|---|---|---|---|---|
| PRIMECAP MANAGEMENT CO/CA/ | $3274304389 | 15154606 | 13.94% | 股份 |
| VANGUARD GROUP INC | $2812686259 | 15982080 | 11.97% | 股份 |
| FMR LLC | $2480996199 | 11482904 | 10.56% | 股份 |
| VANGUARD CAPITAL MANAGEMENT LLC | $2085220339 | 9651117 | 8.88% | 股份 |
| STATE STREET CORP | $1586815292 | 7344327 | 6.75% | 股份 |
| VANGUARD PORTFOLIO MANAGEMENT LLC | $1427062472 | 6604936 | 6.07% | 股份 |
| GEODE CAPITAL MANAGEMENT, LLC | $853425885 | 3965587 | 3.63% | 股份 |
| WELLINGTON MANAGEMENT GROUP LLP | $651741965 | 3016486 | 2.77% | 股份 |
| NORGES BANK | $557441930 | 2580033 | 2.37% | 股份 |
| Boston Partners | $237039714 | 1097693 | 1.01% | 股份 |
| Alyeska Investment Group, L.P. | $201448726 | 932374 | 0.86% | 股份 |
| Pictet Asset Management Holding SA | $184144886 | 851819 | 0.78% | 股份 |
| DIMENSIONAL FUND ADVISORS LP | $183196029 | 847893 | 0.78% | 股份 |
| VANGUARD FIDUCIARY TRUST CO | $179182447 | 829318 | 0.76% | 股份 |
| Robeco Institutional Asset Management B.V. | $170923341 | 791092 | 0.73% | 股份 |
| FRED ALGER MANAGEMENT, LLC | $170321610 | 788307 | 0.72% | 股份 |
| BANK OF AMERICA CORP /DE/ | $156665322 | 725101 | 0.67% | 股份 |
| Employees Provident Fund Board | $152148588 | 704196 | 0.65% | 股份 |
| FIRST TRUST ADVISORS LP | $147357277 | 682021 | 0.63% | 股份 |
| AustralianSuper Pty Ltd | $145348531 | 672723 | 0.62% | 股份 |
| MASSACHUSETTS FINANCIAL SERVICES CO /MA/ | $129114863 | 597588 | 0.55% | 股份 |
| BlackRock, Inc. | $124065973 | 574220 | 0.53% | 股份 |
| Artemis Investment Management LLP | $123364642 | 570974 | 0.53% | 股份 |
| Legal & General Group Plc | $119267279 | 552010 | 0.51% | 股份 |
| Zurcher Kantonalbank (Zurich Cantonalbank) | $116672616 | 540001 | 0.50% | 股份 |
| Caisse de depot et placement du Quebec | $110232516 | 510194 | 0.47% | 股份 |
| UBS Group AG | $108289272 | 501200 | 0.46% | 买入期权 |
| CITADEL ADVISORS LLC | $90389997 | 418356 | 0.38% | 股份 |
| Swiss National Bank | $89427234 | 413900 | 0.38% | 股份 |
| National Pension Service | $87734188 | 406064 | 0.37% | 股份 |
| LMR Partners LLP | $84047340 | 389000 | 0.36% | 买入期权 |
| BNP PARIBAS FINANCIAL MARKETS | $83732325 | 387542 | 0.36% | 股份 |
| Candriam S.C.A. | $82957583 | 384326 | 0.35% | 股份 |
| ROYAL BANK OF CANADA | $78304000 | 362418 | 0.33% | 股份 |
| Mitsubishi UFJ Asset Management Co., Ltd. | $77527297 | 358823 | 0.33% | 股份 |
| Sumitomo Mitsui Trust Group, Inc. | $74890069 | 346617 | 0.32% | 股份 |
| VICTORY CAPITAL MANAGEMENT INC | $74199109 | 343419 | 0.32% | 股份 |
| Fisher Asset Management, LLC | $73032374 | 338018 | 0.31% | 股份 |
| Vanguard Global Advisers, LLC | $72582332 | 335936 | 0.31% | 股份 |
| California Public Employees Retirement System | $71106642 | 329106 | 0.30% | 股份 |
| Swedbank AB | $69271861 | 320614 | 0.29% | 股份 |
| CITADEL ADVISORS LLC | $68058900 | 315000 | 0.29% | 买入期权 |
| GOLDMAN SACHS GROUP INC | $63917486 | 295832 | 0.27% | 股份 |
| LMR Partners LLP | $62268492 | 288200 | 0.27% | 卖出期权 |
| VANGUARD ASSET MANAGEMENT, Ltd | $61442279 | 284376 | 0.26% | 股份 |
| Patient Capital Management, LLC | $61295674 | 283697 | 0.26% | 股份 |
| Gotham Asset Management, LLC | $60475194 | 279900 | 0.26% | 股份 |
| CAUSEWAY CAPITAL MANAGEMENT LLC | $60125780 | 278283 | 0.26% | 股份 |
| PERCEPTIVE ADVISORS LLC | $59669938 | 276173 | 0.25% | 股份 |
| Balyasny Asset Management L.P. | $57275345 | 265090 | 0.24% | 股份 |
| RHUMBLINE ADVISERS | $56819153 | 262979 | 0.24% | 股份 |
| HSBC HOLDINGS PLC | $52886951 | 244779 | 0.23% | 股份 |
| AEGON ASSET MANAGEMENT UK Plc | $52092282 | 241101 | 0.22% | 股份 |
| BNP PARIBAS ASSET MANAGEMENT Holding S.A. | $47304392 | 218941 | 0.20% | 股份 |
| JANE STREET GROUP, LLC | $47122686 | 218100 | 0.20% | 卖出期权 |
| KLP KAPITALFORVALTNING AS | $43034183 | 199177 | 0.18% | 股份 |
| JANE STREET GROUP, LLC | $41289066 | 191100 | 0.18% | 买入期权 |
| CALIFORNIA STATE TEACHERS RETIREMENT SYSTEM | $40458548 | 220687 | 0.17% | 股份 |
| PANAGORA ASSET MANAGEMENT INC | $40387880 | 186929 | 0.17% | 股份 |
| NISSAY ASSET MANAGEMENT CORP /JAPAN | $40036134 | 185301 | 0.17% | 股份 |
| PRINCIPAL FINANCIAL GROUP INC | $39509594 | 182864 | 0.17% | 股份 |
| ALLIANCEBERNSTEIN L.P. | $39411367 | 214975 | 0.17% | 股份 |
| BARCLAYS PLC | $38890800 | 180000 | 0.17% | 卖出期权 |
| BARCLAYS PLC | $37038518 | 171427 | 0.16% | 股份 |
| Quantinno Capital Management LP | $32836341 | 151977 | 0.14% | 股份 |
| MORGAN STANLEY | $32548902 | 150647 | 0.14% | 股份 |
| LETKO, BROSSEAU & ASSOCIATES INC | $31666186 | 146562 | 0.13% | 股份 |
| Portolan Capital Management, LLC | $30865467 | 142856 | 0.13% | 股份 |
| Palo Alto Investors LP | $30308681 | 140279 | 0.13% | 股份 |
| Walleye Trading LLC | $30087003 | 139253 | 0.13% | 股份 |
| O'SHAUGHNESSY ASSET MANAGEMENT, LLC | $29872456 | 138260 | 0.13% | 股份 |
| Nippon Life Global Investors Americas, Inc. | $29647753 | 137220 | 0.13% | 股份 |
| CITADEL ADVISORS LLC | $28995252 | 134200 | 0.12% | 卖出期权 |
| IEQ CAPITAL, LLC | $28550680 | 132142 | 0.12% | 股份 |
| ADAGE CAPITAL PARTNERS GP, L.L.C. | $28001160 | 129599 | 0.12% | 股份 |
| STATE BOARD OF ADMINISTRATION OF FLORIDA RETIREMENT SYSTEM | $26210455 | 121311 | 0.11% | 股份 |
| AMERICAN CENTURY COMPANIES INC | $24663681 | 114152 | 0.10% | 股份 |
| Woodline Partners LP | $24298756 | 112463 | 0.10% | 股份 |
| AVIVA PLC | $23345715 | 108052 | 0.10% | 股份 |
| Eurizon Capital SGR S.p.A. | $22171682 | 102594 | 0.09% | 股份 |
| ADAMS DIVERSIFIED EQUITY FUND, INC. | $21670818 | 100300 | 0.09% | 股份 |
| NEW YORK STATE COMMON RETIREMENT FUND | $21637329 | 100145 | 0.09% | 股份 |
| UBS Group AG | $21607945 | 100009 | 0.09% | 股份 |
| SPHERA FUNDS MANAGEMENT LTD. | $21606000 | 100000 | 0.09% | 买入期权 |
| Balyasny Asset Management L.P. | $21606000 | 100000 | 0.09% | 买入期权 |
| Integral Health Asset Management, LLC | $21606000 | 100000 | 0.09% | 股份 |
| Illinois Municipal Retirement Fund | $21455406 | 99303 | 0.09% | 股份 |
| Susquehanna Portfolio Strategies, LLC | $21346944 | 98801 | 0.09% | 股份 |
| APG Asset Management N.V. | $20973675 | 110984 | 0.09% | 股份 |
| SPHERA FUNDS MANAGEMENT LTD. | $20877014 | 96626 | 0.09% | 股份 |
| LPL Financial LLC | $20626314 | 95466 | 0.09% | 股份 |
| Rhenman & Partners Asset Management AB | $20493291 | 94850 | 0.09% | 股份 |
| PEAK6 LLC | $20374458 | 94300 | 0.09% | 买入期权 |
| STRS OHIO | $20265132 | 93794 | 0.09% | 股份 |
| MANUFACTURERS LIFE INSURANCE COMPANY, THE | $19614791 | 90784 | 0.08% | 股份 |
| Hudson Bay Capital Management LP | $19445400 | 90000 | 0.08% | 股份 |
| VAN ECK ASSOCIATES CORP | $19191313 | 88824 | 0.08% | 股份 |
| Point72 Asset Management, L.P. | $19045473 | 88149 | 0.08% | 股份 |
| ANTIPODES PARTNERS Ltd | $18759842 | 86827 | 0.08% | 股份 |
| MACKENZIE FINANCIAL CORP | $18666288 | 86394 | 0.08% | 股份 |
公司内部人士 83 位内幕人士 · 51 位高管 · 28 位董事
| 内部人士 | 角色 | 上次活动 | 持股数量 | 买入 12个月 | 卖出 12个月 | 净额 12个月 |
|---|---|---|---|---|---|---|
| Christopher Viehbacher | President and CEO | 2026年2月13日 A | 29924 | 0 | 0 | $0 |
| Michel Vounatsos | Chief Executive Officer | 2022年2月18日 J | 67261 | 0 | 0 | $0 |
| George A Scangos | Chief Executive Officer | 2016年7月21日 S | 54779 | 0 | 0 | $0 |
| MULLEN JAMES C | CEO & President | 2010年6月8日 A | 95503 | 0 | 0 | $0 |
| Robin Kramer | Chief Financial Officer | 2026年2月13日 A | 11472 | 0 | 0 | $0 |
| Michael R. Mcdonnell | EVP, Chief Financial Officer | 2025年2月10日 M | 24341 | 0 | 0 | $0 |
| Jeffrey D Capello | EVP & Chief Financial Officer | 2020年2月12日 J | 3118 | 0 | 0 | $0 |
| Paul J Clancy | Executive VP and CFO | 2017年4月25日 S | 10813 | 0 | 0 | $0 |
| KELLOGG PETER N | EVP, Finance and CFO | 2007年3月20日 S | 18966 | 0 | 0 | $0 |
| Robert A Hamm | Chief Operating Officer | 2010年4月23日 S | 27212 | 0 | 0 | $0 |
| HASLER HANS PETER | Chief Operating Officer | 2009年2月24日 A | 53261 | 0 | 0 | $0 |
| William R Rohn | Chief Operating Officer | 2004年11月17日 M | 65462 | 0 | 0 | $0 |
| Adam Keeney | Head of Corporate Development | 2026年5月1日 M | 6365 | 0 | 0 | $0 |
| Sean Godbout | Chief Accounting Officer | 2026年4月1日 M | 1342 | 0 | 0 | $0 |
| Jane Grogan | Head of Research | 2026年2月13日 A | 4058 | 0 | 0 | $0 |
| Nicole Murphy | Head of Pharm Ops and Tech | 2026年2月13日 A | 19611 | 1 | 0 | $585 |
| Rachid Izzar | Head of Global Product Strat. | 2026年2月13日 A | 11011 | 0 | 0 | $0 |
| Singhal Priya | Head of Development | 2026年2月13日 A | 8043 | 0 | 3 | $-734709 |
| Ginger Gregory | EVP, Human Resources | 2026年2月13日 A | 22359 | 0 | 0 | $0 |
| Susan H Alexander | EVP Chief Legal Officer | 2026年2月13日 A | 41807 | 0 | 0 | $0 |
| Chirfi Guindo | Head of Glob Prod Strat & Com | 2022年2月18日 J | 7364 | 0 | 0 | $0 |
| Alphonse Galdes | EVP Pharmaceutical Oper & Tech | 2022年1月19日 A | 5064 | 0 | 0 | $0 |
| Alfred Sandrock | Head of Research & Development | 2021年6月7日 S | 10169 | 0 | 0 | $0 |
| Daniel Karp | EVP, Corporate Development | 2020年2月12日 A | 930 | 0 | 0 | $0 |
| Michael D Ehlers | EVP, Research and Development | 2019年6月1日 J | 8025 | 0 | 0 | $0 |
| Paul Mckenzie | EVP Pharmaceutical Oper & Tech | 2019年3月1日 J | 7235 | 0 | 0 | $0 |
| Gregory F Covino | VP, Chief Accounting Officer | 2018年3月1日 A | 4744 | 0 | 0 | $0 |
| Jean-Paul Kress | EVP Pres Int'l & Global Hd GTO | 2017年7月3日 A | — | 0 | 0 | $0 |
| Adriana Karaboutis | EVP, Tech, Bus. Sol & Corp Aff | 2017年2月28日 M | 8752 | 0 | 0 | $0 |
| Kenneth Dipietro | EVP Human Resources | 2017年2月28日 J | 7177 | 0 | 0 | $0 |
| Adam Koppel | EVP, Strategy and Bus. Dev. | 2016年6月6日 S | 2402 | 0 | 0 | $0 |
| Spyridon Artavanis-Tsakonas | EVP, Chief Scientific Officer | 2016年4月2日 M | 3150 | 0 | 0 | $0 |
| John Cox | EVP Pharmaceutical Oper & Tech | 2016年4月1日 A | 39045 | 0 | 0 | $0 |
| Steven H Holtzman | EVP Corporate Development | 2016年2月23日 J | 8326 | 0 | 0 | $0 |
| Douglas E Williams | EVP Research & Development | 2015年6月19日 S | 11817 | 0 | 0 | $0 |
| Stuart A Kingsley | EVP, Global Comm. Operations | 2015年2月23日 A | 8132 | 0 | 0 | $0 |
| Raymond Pawlicki | SVP, Chief Information Officer | 2013年11月22日 M | 8710 | 0 | 0 | $0 |
| Robert E. Gagnon | Vice President, Finance | 2012年2月29日 S | 3999 | 0 | 0 | $0 |
| Francesco Granata | EVP Global Commercial Operatio | 2012年2月1日 M | 3529 | 0 | 0 | $0 |
| SCHNEIER CRAIG ERIC | EVP, HR, Public Affairs & Comm | 2011年3月1日 M | 10201 | 0 | 0 | $0 |
| Michael F Maclean | SVP, Chief Accounting Officer | 2010年10月1日 F | 10681 | 0 | 0 | $0 |
| Michael Lytton | EVP Corporate & Business Devel | 2010年3月2日 F | 18869 | 0 | 0 | $0 |
| Mark C Wiggins | EVP Corp. and Bus. Dev. | 2008年9月26日 S | 22780 | 0 | 0 | $0 |
| Faheem Hasnain | EVP, Oncology/Rheumatology SBU | 2008年7月9日 M | 25454 | 0 | 0 | $0 |
| ADELMAN BURT A | EVP, Portfolio Strategy | 2007年10月15日 M | 12769 | 0 | 0 | $0 |
| Michael Kowolenko | SVP, Pharm Ops & Technology | 2007年7月25日 M | 18124 | 0 | 0 | $0 |
| Connie Matsui | EVP, Corp. Strategy and Comm. | 2007年2月12日 A | 22837 | 0 | 0 | $0 |
| William H Rastetter | Executive Chairman | 2005年2月23日 J | 373929 | 0 | 0 | $0 |
| Michael Gilman | EVP - Research | 2005年2月17日 A | 23000 | 0 | 0 | $0 |
| BUCKNUM THOMAS J | EVP and General Counsel | 2005年2月17日 A | 5750 | 0 | 0 | $0 |
来自SEC表格3/4/5申报的内部人士;净额=仅公开市场买卖
激进投资者及 5%+ 股东 7 持仓
提交了 SEC Schedule 13D 的投资者 — 持有超过 5% 的受益所有权,意图影响发行人(激进股东持股、董事会活动、并购)。每一行显示该申报人持仓的最新已知状态。
| 申报人 | 已申报 | 持股 | 状态 | 目的 | 申报 |
|---|---|---|---|---|---|
| Biogen Inc. ×8 申报 | 2026年5月14日 | 0.00% | 修订 | 并购/出售 | SEC |
| High River Limited Partnership, Hopper Investments LLC, Barberry Corp., Icahn Partners Master Fund LP, Icahn Partners Master Fund II LP, Icahn Partners Master Fund III LP, Icahn Offshore LP, Icahn Partners LP, Icahn Onshore LP, Icahn Capital LP, IPH GP LLC, Icahn Enterprises Holdings L.P., Icahn Enterprises G.P. Inc., Beckton Corp., Carl C. Icahn ×4 申报 | 2011年6月22日 | — | 初始申报 | — | SEC |
| 2010年3月22日 | — | 初始申报 | — | SEC | |
| 未披露的报告人, 未披露的报告人, 未披露的报告人, 未披露的报告人, 未披露的报告人 | 2010年1月28日 | — | 初始申报 | — | SEC |
| AND | 2008年5月8日 | — | 初始申报 | — | SEC |
| Biogen Idec Inc., Biogen Idec MA Inc. ×3 申报 | 2006年11月9日 | — | 初始申报 | 并购/出售 | SEC |
| 未披露的报告人, 未披露的报告人 | 2001年2月14日 | — | 初始申报 | — | SEC |
Purpose is an automated classification of the filer's own stated purpose (SEC Item 4) — not investment advice. "—" means no clear purpose was stated or the text could not be classified.
ETF持仓 由 197 只交易所交易基金持有
权重仅反映直接股权持仓(N-PORT);杠杆基金或基于衍生品的基金可能持有未显示的额外掉期敞口。
| 基金 | 权重 | 单位 | 截至 | 来源 |
|---|---|---|---|---|
| FXH · First Trust Exchange-Traded Alpha... | 2.23% | 103216 NS | 2026年4月30日 | N-PORT |
| SPIT · RBB Fund, Inc. | 2.11% | 3185 NS | 2026年4月30日 | N-PORT |
| BBP · ETFis Series Trust I | 1.73% | 5434 NS | 2026年4月30日 | N-PORT |
| BIB · ProShares Trust | 1.44% | 5425 NS | 2026年5月31日 | N-PORT |
| TMFX · RBB Fund, Inc. | 1.39% | 2280 NS | 2026年5月31日 | N-PORT |
| CVAR · ETF Opportunities Trust | 1.34% | 2744 NS | 2026年4月30日 | N-PORT |
| JDOC · J.P. Morgan Exchange-Traded Fund ... | 1.30% | 764 NS | 2026年4月30日 | N-PORT |
| NUMV · Nushares ETF Trust | 1.01% | 23096 NS | 2026年4月30日 | N-PORT |
| LABU · Direxion Shares ETF Trust | 0.93% | 25484 NS | 2026年4月30日 | N-PORT |
| ABCS · EA Series Trust | 0.75% | 431 NS | 2026年5月29日 | N-PORT |
| FBCV · FIDELITY COVINGTON TRUST | 0.74% | 6263 NS | 2026年4月30日 | N-PORT |
| FLRG · FIDELITY COVINGTON TRUST | 0.73% | 10857 NS | 2026年4月30日 | N-PORT |
| FTA · First Trust Exchange-Traded Alpha... | 0.72% | 49392 NS | 2026年4月30日 | N-PORT |
| AVMV · AMERICAN CENTURY ETF TRUST | 0.70% | 22249 NS | 2026年5月31日 | N-PORT |
| LSEQ · Harbor ETF Trust | 0.69% | 558 NS | 2026年4月30日 | N-PORT |
| COWZ · Pacer Funds Trust | 0.67% | 642650 NS | 2026年4月30日 | N-PORT |
| QQWZ · Pacer Funds Trust | 0.66% | 1636 NS | 2026年4月30日 | N-PORT |
| ITAN · EA Series Trust | 0.59% | 2701 NS | 2026年5月29日 | N-PORT |
| LSVD · ADVISORS' INNER CIRCLE FUND | 0.58% | 18519 NS | 2026年4月30日 | N-PORT |
| RCGE · EA Series Trust | 0.48% | 2389 NS | 2026年4月30日 | N-PORT |
| FHLC · FIDELITY COVINGTON TRUST | 0.45% | 67622 NS | 2026年4月30日 | N-PORT |
| RXL · ProShares Trust | 0.42% | 1530 NS | 2026年5月31日 | N-PORT |
| CURE · Direxion Shares ETF Trust | 0.40% | 2927 NS | 2026年4月30日 | N-PORT |
| FAB · First Trust Exchange-Traded Alpha... | 0.36% | 2605 NS | 2026年4月30日 | N-PORT |
| AVMC · AMERICAN CENTURY ETF TRUST | 0.35% | 7256 NS | 2026年5月31日 | N-PORT |
| FEX · First Trust Exchange-Traded Alpha... | 0.34% | 26804 NS | 2026年4月30日 | N-PORT |
| JPME · J.P. Morgan Exchange-Traded Fund ... | 0.29% | 6727 NS | 2026年4月30日 | N-PORT |
| GINN · Goldman Sachs ETF Trust | 0.27% | 2960 NS | 2026年5月31日 | N-PORT |
| FLCV · Federated Hermes ETF Trust | 0.27% | 1332 NS | 2026年5月31日 | N-PORT |
| CLSE · Trust for Professional Managers | 0.26% | 8169 NS | 2026年5月31日 | N-PORT |
| AVIE · AMERICAN CENTURY ETF TRUST | 0.26% | 136 NS | 2026年5月31日 | N-PORT |
| CSM · ProShares Trust | 0.25% | 6750 NS | 2026年5月31日 | N-PORT |
| GSLC · Goldman Sachs ETF Trust | 0.23% | 183560 NS | 2026年5月31日 | N-PORT |
| GSEW · Goldman Sachs ETF Trust | 0.20% | 18178 NS | 2026年5月31日 | N-PORT |
| AFLG · First Trust Exchange-Traded Fund ... | 0.19% | 6438 NS | 2026年5月31日 | N-PORT |
| SGLC · RBB Fund, Inc. | 0.19% | 1928 NS | 2026年5月31日 | N-PORT |
| DEUS · DBX ETF Trust | 0.19% | 2624 NS | 2026年5月29日 | N-PORT |
| PALC · Pacer Funds Trust | 0.18% | 2175 NS | 2026年4月30日 | N-PORT |
| CRTC · DBX ETF Trust | 0.13% | 885 NS | 2026年5月31日 | N-PORT |
| CATH · Global X Funds | 0.13% | 8263 NS | 2026年4月30日 | N-PORT |
| FNDX · SCHWAB STRATEGIC TRUST | 0.12% | 159823 NS | 2026年5月31日 | N-PORT |
| USNZ · DBX ETF Trust | 0.12% | 1823 NS | 2026年5月29日 | N-PORT |
| ROUS · Lattice Strategies Trust | 0.12% | 3600 NS | 2026年4月30日 | N-PORT |
| FNDB · SCHWAB STRATEGIC TRUST | 0.11% | 7680 NS | 2026年5月31日 | N-PORT |
| JVAL · J.P. Morgan Exchange-Traded Fund ... | 0.10% | 3945 NS | 2026年4月30日 | N-PORT |
| BRCE · MFS Active Exchange Traded Funds ... | 0.10% | 165 NS | 2026年5月31日 | N-PORT |
| SCHV · SCHWAB STRATEGIC TRUST | 0.09% | 74055 NS | 2026年5月31日 | N-PORT |
| IQSU · New York Life Investments ETF Trust | 0.09% | 1472 NS | 2026年4月30日 | N-PORT |
| DFUV · Dimensional ETF Trust | 0.09% | 66685 NS | 2026年4月30日 | N-PORT |
| USSG · DBX ETF Trust | 0.09% | 2546 NS | 2026年5月29日 | N-PORT |